<p>Evaluations of the calibration and validation of pharmacokinetic models of pamidronate and denosumab.</p
Population pharmacokinetic modelling is widely used within the field of clinical pharmacology as it ...
This repository provides the simvastatin and cholesterol physiological based pharmacokinetics model ...
Pharmacokinetic-pharmacodynamic (PK-PD) models play an important role in educational simulations. Th...
<p>(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmaco...
<p>The calibrated parameter values of the pharmacokinetic models of pamidronate and denosumab.</p
<p>(a) The calibration of the integrated model with denosumab according to the NTX levels. (b) The v...
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
<p>The clinical datasets used for the calibration and validation of the integrated models with pamid...
<p>(a) Denosumab. (b) Pamidronate. m<sub>1</sub>: muscle; m<sub>2</sub>: blood; m<sub>3</sub>: bone....
<p>Note 1: The r<sup>2</sup> is calculated before 30 days after pamidronate treatment.</p><p>Note 2:...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
<p>Pharmacokinetic parameters, estimated with the final two-compartment models.</p
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
The increasing use of tissue dosimetry estimated using pharmacokinetic models in chemical risk asses...
Population pharmacokinetic modelling is widely used within the field of clinical pharmacology as it ...
This repository provides the simvastatin and cholesterol physiological based pharmacokinetics model ...
Pharmacokinetic-pharmacodynamic (PK-PD) models play an important role in educational simulations. Th...
<p>(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmaco...
<p>The calibrated parameter values of the pharmacokinetic models of pamidronate and denosumab.</p
<p>(a) The calibration of the integrated model with denosumab according to the NTX levels. (b) The v...
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
<p>The clinical datasets used for the calibration and validation of the integrated models with pamid...
<p>(a) Denosumab. (b) Pamidronate. m<sub>1</sub>: muscle; m<sub>2</sub>: blood; m<sub>3</sub>: bone....
<p>Note 1: The r<sup>2</sup> is calculated before 30 days after pamidronate treatment.</p><p>Note 2:...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
<p>Pharmacokinetic parameters, estimated with the final two-compartment models.</p
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
The increasing use of tissue dosimetry estimated using pharmacokinetic models in chemical risk asses...
Population pharmacokinetic modelling is widely used within the field of clinical pharmacology as it ...
This repository provides the simvastatin and cholesterol physiological based pharmacokinetics model ...
Pharmacokinetic-pharmacodynamic (PK-PD) models play an important role in educational simulations. Th...
DOI
Add to ORKG